These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35465726)

  • 1. Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis.
    Yanagisawa T; Mori K; Katayama S; Mostafaei H; Quhal F; Laukhtina E; Rajwa P; Motlagh RS; Aydh A; König F; Grossmann NC; Pradere B; Miki J; Schmidinger M; Egawa S; Shariat SF
    Immunotherapy; 2022 Jun; 14(9):709-725. PubMed ID: 35465726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Zhang N; Jiang J; Tang S; Sun G
    Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab.
    Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
    Int J Clin Oncol; 2020 Jan; 25(1):135-144. PubMed ID: 31512006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Young M; Tapia JC; Szabados B; Jovaisaite A; Jackson-Spence F; Nally E; Powles T
    Clin Genitourin Cancer; 2024 Jun; 22(3):102072. PubMed ID: 38615487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Mori K; Abufaraj M; Mostafaei H; Quhal F; Fajkovic H; Remzi M; Karakiewicz PI; Egawa S; Schmidinger M; Shariat SF; Gust KM
    Eur Urol; 2021 Jun; 79(6):783-792. PubMed ID: 33172722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of neutrophil-lymphocyte ratio and lactate dehydrogenase in melanoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Zhang Y; Liu B; Kotenko S; Li W
    Medicine (Baltimore); 2022 Aug; 101(32):e29536. PubMed ID: 35960066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis.
    Shao Y; Wu B; Jia W; Zhang Z; Chen Q; Wang D
    BMC Urol; 2020 Jul; 20(1):90. PubMed ID: 32631294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutrophil-to-lymphocyte Ratio, Platelet-to-lymphocyte Ratio, and C-reactive Protein as New and Simple Prognostic Factors in Patients With Metastatic Renal Cell Cancer Treated With Tyrosine Kinase Inhibitors: A Systemic Review and Meta-analysis.
    Semeniuk-Wojtaś A; Lubas A; Stec R; Syryło T; Niemczyk S; Szczylik C
    Clin Genitourin Cancer; 2018 Jun; 16(3):e685-e693. PubMed ID: 29454639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of the efficacy of the pretreatment neutrophil-to-lymphocyte ratio as a predictor of prognosis in renal carcinoma patients receiving tyrosine kinase inhibitors.
    Na N; Yao J; Cheng C; Huang Z; Hong L; Li H; Qiu J
    Oncotarget; 2016 Jul; 7(28):44039-44046. PubMed ID: 27270655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio, and Platelets in the Prognosis of Metastatic Renal Cell Carcinoma.
    Huszno J; Kolosza Z; Mrochem-Kwarciak J; Rutkowski T; Skladowski K
    Oncology; 2019; 97(1):7-17. PubMed ID: 31048577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The platelet to lymphocyte ratio predicts overall survival better than the neutrophil to lymphocyte ratio in metastatic renal cell carcinoma.
    Aktepe OH; Güner G; Güven DC; Şahin TK; Ardıç FS; Yüce D; Yalçın Ş; Erman M
    Turk J Med Sci; 2021 Apr; 51(2):757-765. PubMed ID: 33350295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta-analysis.
    Tan Q; Liu S; Liang C; Han X; Shi Y
    Thorac Cancer; 2018 Oct; 9(10):1220-1230. PubMed ID: 30151899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy.
    Jeyakumar G; Kim S; Bumma N; Landry C; Silski C; Suisham S; Dickow B; Heath E; Fontana J; Vaishampayan U
    J Immunother Cancer; 2017 Oct; 5(1):82. PubMed ID: 29041991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Patients with Metastatic Renal Cell Carcinoma.
    Parosanu AI; Pirlog CF; Slavu CO; Stanciu IM; Cotan HT; Vrabie RC; Popa AM; Olaru M; Iaciu C; Bratu LI; Baicoianu IF; Moldoveanu O; Baston C; Nițipir C
    Curr Oncol; 2023 Feb; 30(2):2457-2464. PubMed ID: 36826148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen X; Meng F; Jiang R
    Front Oncol; 2021; 11():746976. PubMed ID: 34900692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in prognosticating immunotherapy efficacy.
    Kartolo A; Holstead R; Khalid S; Emack J; Hopman W; Robinson A; Baetz T
    Immunotherapy; 2020 Aug; 12(11):785-798. PubMed ID: 32657234
    [No Abstract]   [Full Text] [Related]  

  • 18. Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy.
    Dharmapuri S; Özbek U; Lin JY; Sung M; Schwartz M; Branch AD; Ang C
    Cancer Med; 2020 Jul; 9(14):4962-4970. PubMed ID: 32419290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review.
    Rebuzzi SE; Perrone F; Bersanelli M; Bregni G; Milella M; Buti S
    Expert Rev Mol Diagn; 2020 Feb; 20(2):169-185. PubMed ID: 31608727
    [No Abstract]   [Full Text] [Related]  

  • 20. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.